Siponimod

79 interactions 5 explained in plain English

Also sold as: Mayzent Mayzent®

About Siponimod

Siponimod is used to prevent episodes of symptoms and slow the worsening of disability in adults with relapsing-remitting forms (course of disease where symptoms flare up from time to time) of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, lo… Read the full Siponimod drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Esmolol Eribulin Injection Penbutolol Acebutolol Felbamate Arsenic Trioxide

78 Major 1 Moderate

All (79) Major (78) Moderate (1)

Major

Siponimod Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Siponimod Sertraline Explained An increased risk of QT interval prolongation Details Siponimod Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Siponimod Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Siponimod Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Siponimod Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Siponimod Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Siponimod Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Siponimod Asciminib Scemblix Increased CYP2C9 substrate exposure and an increased risk of CYP2C9 substrate-related adverse reactions Details Siponimod Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Siponimod Atenolol Tenormin Explained An increased risk of severe bradycardia and heart block Details Siponimod Azithromycin AzaSite An increased risk of QT interval prolongation Details Siponimod Acebutolol Sectral® An increased risk of severe bradycardia and heart block Details Siponimod Alfuzosin UroXatral An increased risk of QT interval prolongation Details Siponimod Anagrelide Agrylin An increased risk of QT interval prolongation Details Siponimod Bedaquiline Sirturo An increased risk of QT interval prolongation Details Siponimod Betaxolol Betoptic S An increased risk of severe bradycardia and heart block Details Siponimod Betaxolol Ophthalmic Betoptic® An increased risk of severe bradycardia and heart block Details Siponimod Bisoprolol Zebeta® An increased risk of severe bradycardia and heart block Details Siponimod Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Siponimod Chloroquine Aralen® An increased risk of QT interval prolongation Details Siponimod Dasatinib Phyrago An increased risk of QT interval prolongation Details Siponimod Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Siponimod Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Siponimod Digoxin Cardoxin® An increased risk of severe bradycardia and heart block Details Siponimod Disopyramide Norpace An increased risk of QT interval prolongation Details Siponimod Dofetilide Tikosyn An increased risk of QT interval prolongation Details Siponimod Dolasetron Anzemet An increased risk of QT interval prolongation Details Siponimod Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Siponimod Encorafenib Braftovi An increased risk of QT interval prolongation Details Siponimod Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Siponimod Eribulin Injection Halaven An increased risk of QT interval prolongation Details Siponimod Esmolol Brevibloc An increased risk of severe bradycardia and heart block Details Siponimod Famotidine Calmicid An increased risk of QT interval prolongation Details Siponimod Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Siponimod Felbamate Felbatol An increased risk of QT interval prolongation Details Siponimod Flecainide Tambocor® An increased risk of QT interval prolongation Details Siponimod Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Siponimod Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Siponimod Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.